Table 1 Demographics and clinical characteristics of migraine patients
From: The potential impact of migraine headache on retinal nerve fiber layer thickness
Migraine patients (n = 40) | Controls (n = 40) | P-value | |
|---|---|---|---|
Age in years [mean (SD)] | 32.85 (8.76) | 33.2750 (9.2) | 0.833 |
Sex | |||
Males [n (%)] | 18 (45%) | 22 (55%) | 0.371 |
Females [n (%)] | 22 (55%) | 18 (45%) | |
Disease duration in years [median (IQR)] | 3.5 (2–10) | ||
Type of migraine | |||
Episodic [n (%)] | 12 (30%) | ||
Chronic [n (%)] | 28 (70%) | ||
Frequency of the attacks/month | 20 (10–20) | ||
Attack duration in hours [median (IQR)] | 5.5 (4–24) | ||
MIGSEV scale | |||
Intensity [median (IQR)] | 2.5 (2–3) | ||
Disability [median (IQR)] | 3 (2–3) | ||
Tolerability [median (IQR)] | 2 (2–3) | ||
Nausea [median (IQR)] | 2 (2–3) | ||
Aura | |||
Present [n (%)] | 20 (50%) | ||
Absent [n (%)] | 20 (50%) | ||
Abortive treatment | |||
Paracetamol [n (%)] | 16 (40.0%) | ||
NSAIDS [n (%)] | 29 (72.5%) | ||
Triptans [n (%)] | 13 (32.5%) | ||
Response to abortive treatment | |||
Poor [n (%)] | 22 (55%) | ||
Moderate [n (%)] | 14 (35%) | ||
Excellent [n (%)] | 4 (10%) | ||
Prophylactic treatment | |||
None [n (%)] | 26 (65.0%) | ||
Anti-epileptics [n (%)] | 7 (17.5%) | ||
Anti-depressants [n (%)] | 7 (17.5%) | ||